Cancer.Net   
 Journal of Clinical Oncology   
 Journal of Oncology Practice   
 ASCO News & Forum   
 The ASCO Cancer Foundation   
 ASCO Press Center   
 

Home > News > Press Center > Annual Meeting > News Releases


Studies Examine Efficacy of Complementary and Alternative Medicine for Cancer


CONTACT:
Annual Meeting News Room
312-949-3200

ASCO Media Information Line
212-584-5010

-- PRESS BRIEFING SATURDAY, JUNE 2, 9:30 AM CDT --

-- Ginseng May Help Combat Fatigue in Cancer Patients;
Flaxseed May Stall Prostate Cancer Growth;
Shark Cartilage Extract Does Not Improve Survival in Patients
with
Non-Small Cell Lung Cancer --

CHICAGO—Studies examining the efficacy of several complementary and alternative treatments for cancer and its side effects were discussed today at a press briefing of the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO).

“The use of complementary and alternative medicine to treat cancer and its side effects has been widespread, but there have been few studies designed to scientifically evaluate whether a particular approach is effective,” said Bruce D. Cheson, MD, head of hematology at the Lombardi Comprehensive Cancer Center and Georgetown University Hospital, and moderator of the press briefing. “Today we report on two dietary supplements that show early promise for helping cancer patients, and another controversial treatment that provides no benefit at all in lung cancer patients.”

Study findings include:

  • The herb ginseng may decrease fatigue, one of the most common and debilitating side effects of cancer and its treatment.

  • Flaxseed may slow the growth of prostate tumors.

  • Adding shark cartilage extract to treatment with standard chemotherapy and radiation therapy does not improve survival in patients with advanced non-small cell lung cancer.
For consumer-oriented information on these studies and more than 120 cancer types and cancer-related syndromes, please refer your readers to ASCO’s oncologist-vetted patient Web site, www.plwc.org.

View full press release.